The firm is completing a clinical study that it hopes will facilitate the launch of its AST system that provides results in four hours after a positive blood culture.
The companies are positioning the test, called SeptiCyte Rapid, for use in triaging COVID-19 patients who could be at greater risk for progressing to sepsis.
Intalere member hospitals will receive access to Magnolia's alliance member pricing and clinical performance guarantee for Steripath under the agreement.
Sepset said its early test for sepsis, a condition that requires rapid diagnosis and treatment, would give clinicians valuable time to identify treatment strategies.
